ABSTRACT: In Exp. 1, individual performance and daily DMI was measured on 70 crossbred weaned calves during a 70-d period using a GrowSafe system (GrowSafe Systems Ltd., Airdrie, AB, Canada) at the University of Florida North Florida Research and Education Center Feed Efficiency Facility (FEF). Calves were fed a low-concentrate (LC) growing diet, blocked by weight and sex, and then randomly assigned to pens to receive either no additional supplement (CON; n = 35) or receive a supplement of anti-phospholipase A 2 antibody (aPLA2) at an inclusion rate of 0.6% of the diet DM (n = 35). After the 70-d feed efficiency (FE) trial (Phase 1), calves were loaded into a commercial livestock trailer and were driven for approximately 1,600 km during 24 h. Upon return to the FEF (Phase 2), calves were relocated to the same pens and groups and received the same diets and treatments for 28 d. Blood samples from each calf were collected on d 0, 1, 3, 5, 7, 14, 21, and 28 relative to initiation of transportation and were analyzed for determination of concentrations of plasma ceruloplasmin and haptoglobin. In Phase 1, initial BW (242.0 ± 3.7 kg; P = 0.92), BW at d 70 (313.0 ± 4.1 kg; P = 0.79), and ADG (1.01 ± 0.02 kg; P = 0.95) were similar between treatments. However, daily DMI
INTRODUCTION
Transportation is one of the most common and intense acute physical stressors that cattle encounter throughout the production cycle, leading to physiological, nutritional, and immunological changes with activation of the acute-phase response (APR) that can affect subsequent health and performance (Loerch and was greater (P = 0.01) for CON (9.18 ± 0.15 kg) than aPLA2 (8.53 ± 0.15 kg). In addition, residual feed intake was greater (P = 0.002) for CON (0.389 ± 0.110 kg/d) than aPLA2 calves (-0.272 ± 0.110 kg/d). In Phase 2, after transportation, there were no differences between treatments on BW loss due to transportation shrink (26.0 ± 0.6 kg; P = 0.86), BW at d 28 (339.0 ± 4.1 kg; P = 0.72), ADG (1.28 ± 0.03 kg/d; P = 0.72), G:F (0.164 ± 0.004; P = 0.83), and concentrations of plasma haptoglobin (0.08 ± 0.02 mg/mL; P = 0.41). However, concentrations of plasma ceruloplasmin were greater (P < 0.001) for CON calves (14.3 ± 0.3 mg/ dL) compared to aPLA2 calves (13.0 ± 0.3 mg/dL). In Exp. 2, the effects of aPLA2 inclusion on LC and high-concentrate (HC) substrates on in vitro fermentation parameters were assessed. Addition of aPLA2 had no effects on in vitro fermentation parameters of LC and HC substrates. In conclusion, supplementation of aPLA2 improved FE of growing beef calves when fed LC diets in Phase 1 and addition of aPLA2 had no effect on fermentation parameters of LC and HC substrates. In addition, calves supplemented with aPLA2 had reduced concentrations of plasma ceruloplasmin after 24 h of transportation. Fluharty, 1999; Arthington et al., 2003; Araujo et al., 2010) . Upon activation of the immune system and the APR, an organism diverts nutrients away from growth and development, redirecting it into defense processes (Johnson, 1997) followed by immediate decrease in feed intake, wasting of skeletal muscle, increased lipolysis and production of acute-phase proteins (APP) by the liver, plasma mineral alterations, fever, and changes in behavior (Johnson, 1997; Cook, 2011; Cooke and Bohnert, 2011) .
One theory hypothesizes that pathogens and lipopolysaccharides (LPS) translocate into the bloodstream through activation of secretory phospholipase A 2 (sPLA 2 ) in the intestinal lumen, and once in the bloodstream, LPS stimulates leukocyte production of proinflammatory cytokines with further activation of the APR, leading to physiological responses that have direct effects on animal performance (Cook, 2011) . Feed efficiency (FE) and growth was improved in a series of studies with poultry, swine, and fish using an egg-derived antibody against sPLA 2 (anti-phospholipase A 2 antibody [aPLA 2 ]) as a feed additive (Yang et al., 2003; Cook, 2004 Cook, , 2011 Barry and Yang, 2008) . However, the use of aPLA 2 as a feed additive for cattle diets has not been reported.
Therefore, cattle that consume aPLA 2 may have decreased inflammatory response and, consequently, enhanced performance and improved FE. In 1 in vivo and 1 in vitro experiment, the objectives were to determine whether supplementation of aPLA 2 would alter overall performance of growing beef calves receiving a background diet and alleviate the APR associated with transportation and alter in vitro fermentation parameters of low-concentrate (LC) and high-concentrate (HC) substrates.
MATERIALS AND METHODS
All procedures for the study conducted at the North Florida Research and Education Center (NFREC; Marianna, FL) were approved by the University of Florida Institutional Animal Care and Use Committee. Before initiation of these experiments, using a bioassay, we determined whether active aPLA 2 antibody was present in the lower digestive tract from duodenal digesta samples collected from duodenal cannulated steers receiving a forage based diet with either an aPLA 2 supplement or no supplement. The results demonstrated the presence of active aPLA 2 antibody within the duodenal samples of the steers receiving the aPLA 2 antibody supplement (data not included).
Experiment 1
Animals and Treatments. For Phase 1, 70 crossbred weaned beef calves (n = 53 steers and n = 17 heifers) were allocated to pens (108 m 2 /pen; 2 pens of 11 animals each and 4 pens of 12 animals each) at the NFREC Feed Efficiency Facility (FEF). Calves were submitted to a 70-d FE trial before transportation and individual daily DMI was measured using the GrowSafe system (GrowSafe Systems Ltd., Airdrie, AB, Canada). Each pen in the FEF was equipped with 2 GrowSafe feed bunks. Calves were blocked by weight and sex and then randomly assigned to pens to receive treatments. A 21-d period of adaptation to facilities and diets preceded the 70-d FE trial. Body weight was recorded at 14-d intervals over the 70-d period.
Calves were assigned to receive a growing total mixed ration (TMR) diet (0.6 Mcal NEg/kg DM and 13% CP; Table 1 ). Calves received either an additional supplement of estimated daily DMI containing an anti-phospholipase A 2 dried whole-egg antibody (BIG BEEF; Aova Technologies, Madison, WI; Cook and Trott, 2010 ; 3 pens; n = 35 for aPLA 2 ) at an inclusion rate of 0.6% of the diet DM or no additional supplement (CON; 3 pens; n = 35). The antibody supplement was delivered using a premix with soy hulls containing the aPLA 2 at a concentration of 30% (DM basis). The antibody premix was included in the TMR diet at 2% of the diet DM, while control animals received an additional 2% of soy hulls in the diet DM. Phase 2 was initiated immediately after completion of the 70-d FE trial. On d 0, calves were loaded into a commercial livestock trailer and driven within the state of Florida for approximately 1,600 km during a 24-h period before returning and being unloaded at the FEF, on d 1. Due to a limit in the maximum weight of the livestock trailer, 4 calves (2 of each treatment, the heaviest and lightest calves) were not loaded into the trailer and were subsequently excluded from the statistical analysis for Phase 2. Upon return to the FEF, calves were relocated to the same pens and groups and received the same diets and treatments of Phase 1. Body weight was determined on d 0 immediately before shipping and immediately on arrival on d 1, and a shrunk BW (16 h following removal from feed) was determined on the final day of Phase 2, on d 28.
Blood Collection and Analyses. Blood samples from each calf were collected from the jugular vein into 10-mL evacuated glass vials containing 143 IU of sodium heparin (Vacutainer; Becton Dickinson Inc., Franklin Lakes, NJ) on d 0 immediately before shipping and immediately on arrival on d 1, 3, 5, 7, 14, 21 , and 28 relative to transportation. Blood samples were immediately placed on ice and centrifuged at 1,500 × g at 4°C for 15 min. The plasma was transferred by pipette into polypropylene vials (12 by 75 mm; Fisherbrand; Thermo Fisher Scientific Inc., Waltham, MA) and stored at -20°C until further analysis.
A spectrophotometer (ThermoSpectronic Genesys 20; Thermo Fisher Scientific Inc.) was used to determine concentrations of plasma ceruloplasmin. The plasma ceruloplasmin oxidase activity was measured in duplicate samples using colorimetric procedures as previously described by Demetriou et al. (1974) . Concentrations of ceruloplasmin were expressed as milligrams per deciliter (King, 1965) . The intra-and interassay CV for ceruloplasmin were 2.1 and 4.8%, respectively. A microplate spectrophotometer (Power Wave 340; BioTek Instruments, Inc., Winooski, VT) was used to determine concentrations of plasma haptoglobin in duplicate samples by measuring haptoglobin/hemoglobin complexing by the estimation of differences in peroxidase activity as described previously (Makimura and Suzuki, 1982) , and results are expressed as arbitrary units from the absorption reading at 450 nm of wavelength × 100. The intra-and interassay CV for haptoglobin were 5.9 and 4.9%, respectively.
Feed Sample Collection and Analyses. Representative samples of each treatment TMR diet were taken before feeding and at 28-d intervals throughout phases 1 and 2. All samples were bagged and frozen immediately after collection until drying. All feed samples analyzed for nutritive values were dried at 55°C for 48 h in a forced-air oven. At the conclusion of the drying period, all samples were ground in a Wiley mill (Arthur H. Thomas Co., Philadelphia, PA) using a 1.0-mm screen. After grinding, samples were composited for analysis on an equal weight basis. The composited samples were analyzed for DM, CP, TDN, ADF, NDF, Ca, and P in duplicate by a commercial laboratory (Dairy One Forage Laboratory, Ithaca, NY).
Statistical Analysis. For Phase 1, linear regression of BW against day on trial was used to establish ADG, using the SLOPE function of Excel (Microsoft, Redmond, WA). The G:F was computed as the ratio of ADG to daily DMI. Residual feed intake (RFI) was calculated as the actual DMI minus the expected DMI, with the expected DMI derived from the regression of the actual DMI on ADG and midtest metabolic BW using the regression equations provided by the GLM procedure of SAS (SAS Inst. Inc., Cary, NC). The MIXED procedure of SAS was used to identify differences in initial BW, final BW, ADG, daily DMI, G:F, and RFI with animal as the experimental unit; the statistical model included treatment, pen within treatment, sex, and all 2-and 3-way interactions.
For Phase 2, individual calf ADG was determined by the difference between the final shrunk BW and the initial shrunk BW on arrival on d 1 divided by the number of days on trial. Body weight loss (BWL) after transportation was calculated as the difference between BW on d 0 and BW on d 1, the percentage of BWL (%BWL) was calculated as the ratio between BWL and BW on d 0 multiplied by 100, and G:F was calculated as the ratio of ADG to daily DMI. The MIXED procedure of SAS was used to identify differences in BW on d 0, BW on d 1, BWL, %BWL, daily DMI, G:F, and back fat with animal as the experimental unit; the statistical model included treatment, pen within treatment, sex, and all 2-and 3-way interactions.
The repeated measures statement of the MIXED procedure of SAS was used to analyze differences in concentrations of haptoglobin and ceruloplasmin. The statistical model included treatment, day, sex, and all 2-and 3-way interactions, with day as the repeated variable, animal as the subject, and block (low, medium, and high BW) as random effect. For differences in daily DMI after transportation, the repeated measures statement of the MIXED procedure of SAS was used. The statistical model included treatment, day or week, sex, and all 2-and 3-way interactions, with day or week as the repeated variable, animal as the subject, and block (low, medium, and high BW) as random effect. The GLM procedure of SAS was used to assess the correlation between concentrations of ceruloplasmin and haptoglobin with DMI on d 0, 1, 3, 5, 7, and 14 following transportation. Statistical differences reported at P ≤ 0.05 were considered significant and 0.05 > P ≤ 0.10 were considered tendencies, with means being reported as least squares means ± SEM.
Experiment 2
Feed Sample Collection, Analyses, and Substrate Preparation. In vitro batch culture incubations were conducted using a LC and a HC substrate. The composition and analyzed nutrient content of LC and HC substrates are described in Table 2 . The aPLA 2 was included in both LC and HC substrates at 0.0, 0.2, and 0.4% of substrate DM. Monensin (MON) was included in 1 of the treatments as a positive control and was added dissolved in ethanol at a dose of 4 mg/L of incubation volume and with a final concentration of 0.2% ethanol (vol/vol) in the incubation fluid. These combinations of substrates and treatments were used to evaluate in vitro true DM digestibility (IVTDMD), gas production kinetics, hydrogen sulfide (H 2 S) and methane (CH 4 ) production, and ammonia nitrogen (NH 3 -N) and VFA concentrations.
Before inclusion in the substrates, all ingredients were air dried for at least 48 h and ground to pass a 2-mm screen (except the aPLA 2 that was in a powdered form and urea, which was ground using mortar and pestle) in a Wiley mill (Arthur H. Thomas Co.). Substrates were sent to a commercial laboratory (Dairy One Forage Laboratory) for nutrient composition analyses.
In Vitro Incubations and Analysis. Substrates were incubated for 24 h at 39°C under constant agitation (60 rpm) in 250-mL bottles, and gas production kinetics were recorded using a the Ankom Gas Monitoring System (Ankom Technologies). Bottles containing 1.4 g of substrate and 100 mL of inoculum were incubated for 24 h, and VFA concentrations were measured at the end of the incubation period along with NH 3 -N concentrations, final pH, and H 2 S and CH 4 production. Incubations were repeated on 3 separate days and 2 bottles per treatment were incubated each day. At the end of the incubation period, the fermentation was stopped by adding 1 mL of a 20% H 2 SO 4 solution to each bottle. Immediately afterwards, a 10-mL sample was taken and frozen for subsequent VFA and NH 3 -N analyses. Ruminal fluid was collected from 2 ruminally cannulated Angus crossbred steers (601 ± 16.0 kg of BW). The steers were grazing a bahiagrass (Paspalum notatum) pasture for at least 2 wk before collection of rumen fluid for inoculum for the LC substrates. For the HC substrate incubations, ruminal fluid donor steers grazed a bahiagrass pasture with ad libitum access to 85% concentrate diet, consisting mainly of corn gluten feed and soybean hulls, for at least 2 wk before incubations. Ruminal fluid was strained from a representative sample of digesta through 4 layers of cheese cloth, placed in a prewarmed thermos container, and transported to the laboratory within 30 min of collection. A 3:1 McDougall's buffer:ruminal fluid mixture was used as inoculum for the LC substrate incubations, while a 2:1 buffer:ruminal fluid mixture was used for the HC substrate incubations.
Methane and Hydrogen Sulfide Production and Ammonia Nitrogen Analysis. Total gas produced in the 250-mL bottles was collected in a 1-L Tedlar gas collection bag (Supelco International, Bellefonte, PA) attached to the Ankom Gas Monitoring modules (Ankom Technology Corp., Macedon, NY). The gas in the Tedlar bag was analyzed for CH 4 and H 2 S concentration. To determine H 2 S production, 5 mL of gas from the Tedlar bag was bubbled slowly into 15-mL evacuated tubes (BD Vacutainer; Becton Dickinson Inc.) containing 5 mL of alkaline water prepared as described by Smith et al. (2010) . The tubes were then vigorously shaken to ensure proper dispersion of the gas in the alkaline water. An injection of 0.5 mL of N,N-dimethyl-pphenylenediamine sulfate was made into the tubes followed by 0.5 mL of ferric chloride. Tubes were again vigorously shaken and allowed to rest for 30 min for the reaction to occur (Smith et al., 2010) . Absorbance was read at 665 nm using a spectrophotometer (DU 530; Beckman Coulter Inc., Palo Alto, CA).
Concentrations of NH 3 -N in the incubation fluid were measured after centrifuging at 10,000 × g for 15 min at 4°C (Avanti J-E; Beckman Coulter Inc.) following the phenol-hypochlorite technique described by Broderick and Kang (1980) with the following modification: absorbance was read at 620 nm in flatbottom 96-well plates using a plate reader (DU-500; Beckman Coulter Inc.). Volatile Fatty Acids Analyses. Volatile fatty acids of the samples were determined in a water-based solution using an ethyl acetate extraction. Samples were centrifuged for 10 min at 10,000 × g at 5°C.. Five milliliters of the ruminal fluid supernatant was mixed with 1 mL of a meta-phosphoric acid:crotonic acid (internal standard) solution and samples were frozen overnight, thawed, and centrifuged for 10 min at 10,000 × g at 5°C. Supernatant was transferred into vials and mixed with ethyl acetate in a 2:1 ratio of ethyl acetate to supernatant. After vigorously shaking vials, the ethyl acetate fraction rose to the top and a subsample was transferred to a vial. Samples were analyzed by gas chromatography (Agilent 7820A GC; Agilent Technologies, Palo Alto, CA) using a flame ionization detector and a capillary column (CP-WAX 58 FFAP 25 m 0.53 mm, Varian CP7767; Agilent Technologies, Inc., Santa Clara, CA).
In Vitro True Dry Matter Digestibility. In vitro true DM digestibility was measured using 200-mL plastic scintillation vials with rubber stoppers fitted with a 16-gauge needle for gas release. Tared vials containing 0.7 g of substrate and 50 mL of a 3:1 or a 2:1 mixture of McDougall's buffer:ruminal fluid for LC and HC substrates, respectively, were incubated for 24 h at 39°C under constant agitation (60 rpm). Two vials per treatment and 2 blank vials (without substrate) were incubated in each of 3 separate replicate days. Afterwards, incubation vials were immediately frozen at -20°C for a minimum of 16 h and freeze-dried for 24 h (FreeZone 6 L Freeze Dryer System; Labconco Corp., Kansas City, MO). Following freeze drying, vials were placed overnight in a 100°C oven and weighed to calculate remaining DM. To calculate IVTDMD for each vial, the dry residue weight (corrected for the contribution of solids in the blank) was subtracted from the incubated DM and the result (i.e., digested DM) was divided by the dry weight of substrate incubated.
Statistical Analysis. Gas production kinetics parameters were quantified using a modified Gompertz model (Schofield et al., 1994) and were fitted to time-course data obtained from the Ankom wireless module system (Ankom Technology Corp., Macedon, NY) by the NLIN procedure of SAS. The parameters of this model were lag time (h), asymptotic maximal gas production, and fractional rate of gas production (%/h), calculated by dividing the absolute rate of gas production (mL/h) by volume. The IVTDMD, gas production kinetics, methane, NH 3 -N, H 2 S, final pH, and VFA data were analyzed using the MIXED procedure of SAS, with block (incubation day) as a random effect, with incubation bottle as the experimental unit. Orthogonal polynomial contrasts were used to determine linear, quadratic, and cubic effects of aPLA 2 inclusion. Statistical differences were reported at P ≤ 0.05 were considered significant and 0.05 ≤ P ≤ 0.10 considered tendencies, with means being reported as least squares means ± SEM.
RESULTS AND DISCUSSION

Experiment 1
Animal Performance and Feed Efficiency during Phase 1. Animal performance and FE data for Phase 1 are summarized in Table 3 . There were no differences between treatments in initial BW, final BW, and ADG during Phase 1. Mean daily DMI during the 70-d FE trial was greater (P < 0.01) for CON (9.18 ± 0.15 kg) compared to aPLA 2 (8.53 ± 0.15 kg). There was a treatment × week interaction (P < 0.01) on average daily DMI and daily DMI was greater (P < 0.01) for CON calves during wk 1, 2, 7, and 8 and tended (P < 0.10) to be greater during wk 9 and 10 of the 70 d trial compared to calves in the aPLA 2 treatment (Fig. 1) . Residual feed intake was lower (P < 0.01) for aPLA 2 calves (-0.272 ± 0.110 kg/d) than for CON calves (0.389 ± 0.110 kg/d). There was also a tendency (P = 0.09) for the aPLA 2 treatment to have greater G:F than the CON treatment (0.117 ± 0.003 and 0.110 ± 0.003 for aPLA 2 and CON, respectively). Supplementation of aPLA 2 reduced daily DMI while maintaining ADG and final BW similar to CON calves, improving FE. Similarly, supplementation of aPLA 2 improved FE and growth of broilers by 3.8 and 5.3%, respectively (Cook, 2004 (Cook, , 2011 . Several other reports of improvements on FE and growth of swine and fish supplemented with aPLA 2 have been reported, without increasing morbidity and mortality due to infectious diseases (Yang et al., 2003; Schwartz et al., 2006; Barry and Yang, 2008) . Germ-free and antibiotic fed chickens have decreased thickness and weight of the intestine that is largely attributed to accumulation of immune cells and enzymes to build a defense barrier against microorganisms on the intestinal lumen (Lev and Forbes, 1959; Drew et al., 2003; Cook, 2004) . Lipopolysaccharides are commonly present in rumen fluid, and translocation of LPS into the bloodstream can occur, especially under immunological stress and ruminally acidotic conditions (Andersen et al., 1994; Gozho et al., 2007; Emmanuel et al., 2007 Emmanuel et al., , 2008 Khafipour et al., 2009; Ametaj et al., 2009; Dong et al., 2011) . The translocation of LPS and other toxins are mediated by sPLA 2 when the intestinal phospholipid barrier has been disrupted, causing release of free AA in the cytosol and increased production of prostaglandins, with further activation of the APR and production of proinflammatory cytokines (Johnson, 1997; Rozenfeld et al., 2001; Zayat et al., 2008; Cook, 2011) . Regulation of the intestinal immune stimulation could reduce intestinal thickness improving nutrient absorption, reduce the energy costs associated with the maintenance of the intestinal immune barrier, and reduce the detrimental effects of the activation of APR with production of proinflammatory cytokines over animal performance, explaining the decreased DMI and FE improvement observed on calves treated with aPLA 2 .
Animal Performance and Feed Efficiency during Phase 2. Animal performance and FE data for Phase 2 are summarized in Table 4 . There were no differences in BW before (d 0; P = 0.73) and after (d 1; P = 0.65) 24 h of transportation and final BW (d 28; P = 0.72). No difference in mean BWL after 24 h of transportation (26.2 ± 0.6 and 25.9 ± 0.6 kg for CON and aPLA 2 calves, respectively) was detected. Weight loss after transportation of beef calves ranges from 6 to 10%, and the amount of weight loss was directly dependent on body condition before transportation, pretransit diets, and duration of transportation (Fike and Spire, 2006) . The percentage of BWL after 24 h of transportation did not differ (P = 0.73) between treatments; calves from both treatments had an 8.1 ± 0.1% reduction in BW during transportation.
There were no differences in ADG (P = 0.72), average DMI (P = 0.45), and G:F (P = 0.83) between treatments during the 28 d following 24 h of transportation (Table 4) . Beef calves have decreased DMI after transportation, especially within the first 2 wk following transportation, and the decrease in DMI was more dramatic when there was a combination of stressors such as transportation, commingling, and introduction to new diets that have greater contents of concentrate (Loerch and Fluharty, 1999; Arthington et al., 2003; Duff and Galyean, 2007) . In the present study, a decrease in DMI following transportation occurred (P = 0.03); however, there was no treatment differences (P = 0.26) in the decrease in DMI d 0 to 1 (2.43 ± 0.15 kg; Table 4 ). In addition, calves in the aPLA 2 and CON treatments had similar decrease in average daily DMI (10 and 13% decrease, respectively) within the first 2 wk following transportation compared with average daily DMI on the 2 wk that preceded transportation. In this study, calves were maintained on the same diets and group pens during pre-and posttransportation periods, eliminating the stress associated with commingling and dietary changes, which may have attributed similar decreases in DMI following transportation.
There were treatment (P = 0.02) and treatment × day (P < 0.0001) effects on daily DMI during the first 15 d following transportation (Fig. 2) . Calves consuming the aPLA 2 supplement had reduced average DMI compared to CON calves (8.45 ± 0.18 and 8.82 ± 0.17 kg for aPLA 2 and CON, respectively) during the first 15 d following transportation. Calves in the CON group had greater daily DMI than aPLA 2 calves on d 1, 6, and 8 and lower daily DMI on d 7. The reduced DMI during the first 15 d following transportation of aPLA 2 calves reflects a continuation of the lower DMI during Phase 1 and reinforces the hypothesis that calves receiving the aPLA 2 may have reduced energy requirements for maintenance of the intestinal local immune response, allowing more available energy and nutrients to cope with stress and physiological processes, resulting in reduced DMI.
Acute-Phase Response during Transportation. Concentrations of haptoglobin and ceruloplasmin peaked on d 3 (day effect, P < 0.0001) after transportation, indicating that calves experienced an APR (Arthington et al., 2008) . Activation of the APR is a normal immunological reaction of an organism to stress and is characterized by increased concentrations of proinflammatory cytokines and APP (Johnson, 1997) . On d 3, supplementation of aPLA 2 did not affect (P = 0.41) concentrations of plasma haptoglobin after 24 h of transportation and no treatment × day interaction existed (P = 0.21; Fig. 3 ). In addition, no treatment × day interaction was detected (P = 0.98) for concentrations of plasma ceruloplasmin. However, a treatment effect (P < 0.001) existed for concentrations of plasma ceruloplasmin after transportation. Calves receiving aPLA 2 supplementation had reduced concentrations of plasma ceruloplasmin throughout the 28 d that followed transportation compared to CON calves (Fig. 4) , indicating that aPLA 2 supplementation successfully reduced the APR to 24 h of transportation. Ceruloplasmin is the major copper-carrying protein in the blood and also participates in iron homeostasis (Arthington et al., 1996) . It is possible that an effect of the aPLA 2 antibody on copper metabolism could occur, explaining the lower ceruloplasmin concentrations on d 0 (Fig. 4) before transportation. However, such possibility was not anticipated and therefore could not be tested. Independent of treatments, mean concentrations of plasma ceruloplasmin were negatively correlated (R 2 = 0.35, P < 0.001) with average daily DMI during the first 2 wk after transportation (Fig. 5) , but no correlation (P = 0.77) between average daily DMI and concentrations of plasma haptoglobin was detected. Concentrations of ceruloplasmin after transportation have been negatively correlated with ADG and positively correlated with concentrations of cortisol (Arthington et al., 2003; Cooke et al., 2009; Araujo et al., 2010) .
Beef calves receiving a LC growing diet supplemented with aPLA 2 had reduced average daily DMI while maintaining ADG similar to CON calves, resulting in lower RFI and improved FE during the 70-d trial. In addition, calves supplemented with aPLA 2 had reduced concentrations of plasma ceruloplasmin after 24 h of transportation, indicating a reduction in the magnitude of the APR and its negative effects on animal performance. 3 Standard error of treatment means; n = 2 reps/treatment on 3 separate days.
4 Observed significance levels for treatment effects and for linear and quadratic effects of increasing aPLA 2 dose. 5 IVTDMD = in vitro true DM digestibility.
6 Parameters estimated by fitting to a modified Gompertz function, in which M = maximal gas production, Kf = fractional gas production, and lag phase = duration of the lag phase. 
Experiment 2
In Vitro Incubation and Gas Production. Gas production, IVTDMD, H 2 S, NH 3 -N, and pH for the LC substrate incubation are summarized in Table 5 . Addition of aPLA 2 to LC substrates had no effect on in vitro fermentation parameters and gas production. However, there was a decrease (P < 0.05) in IVTDMD, H 2 S, and maximal gas production when MON was added. Inclusion of MON increased pH while addition of aPLA 2 decreased pH, with the CON being intermediate (P < 0.05). There was also a tendency (P = 0.09) for MON to reduce concentrations of NH 3 -N compared with the 0.4% inclusion of aPLA 2 . Similarly, other studies using the rumen simulation technique reported that addition of MON to LC substrates incubated in ruminal fluid from sheep had decreased digestibility, gas production, and NH 3 -N concentration (Goiri et al., 2009a,b) . Addition of MON to the LC substrate incubation also decreased (P < 0.0001) in vitro production of CH 4 (Table 5 ), while addition of aPLA 2 had no effect compared with the CON. Monensin has antimi- 3 Standard error of treatment means; n = 2 reps/treatment on 3 separate days.
6 Parameters estimated by fitting to a modified Gompertz function, in which M = maximal gas production, Kf = fractional gas production, and lag phase = duration of the lag phase. 3 Standard error of treatment means; n = 2 reps/treatment on 3 separate days.
crobial effects targeting gram positive bacteria, such as methanogens, reducing microbial activity in the rumen and resulting in decreased digestibility and gas production (Appuhamy et al., 2013) . Furthermore, addition of MON to LC substrate incubation had no effects on total VFA production but reduced (P < 0.05) production of acetate, isobutyrate, butyrate, isovalerate + 2 methylbutyrate, and acetate to propionate ratio in comparison to aPLA 2 and CON groups (Table 6 ). Gas production, IVTDMD, H 2 S, NH 3 -N, and pH for the HC substrate incubation are summarized in Table 7 . Addition of aPLA 2 to HC substrates had no effect on in vitro fermentation parameters and gas production. Similarly, the LC substrate incubation addition of MON tended (P = 0.07) to decrease IVTDMD when compared to aPLA 2 treatments but had no effect on maximal gas production, H 2 S, and NH 3 -N, when compared to aPLA 2 and CON treatments. Addition of MON increased (P = 0.005) pH of HC substrate in in vitro fermentation compared to aPLA 2 and CON. Monensin has been shown to decrease lactic acid concentration in the rumen, therefore increasing ruminal pH (Nagaraja and Titgemeyer, 2007) . In a similar study using the same MON dose on HC substrates, no effect of MON addition on H 2 S was found, in agreement with our findings; however, no effect of MON on IVTDMD was observed (Smith et al., 2010) . Methane production was not affected by aPLA 2 addition; however, addition of MON decreased (P < 0.01) in vitro production of CH 4 (Table  7) in agreement with other reports (Goiri et al., 2009b; Smith et al., 2010) . Total VFA production was not affected (P = 0.93) by aPLA 2 or MON addition. However, MON tended (P = 0.08) to decrease acetate production compared to the CON and 0.4% aPLA 2 treatment. Addition of MON also decreased (P < 0.05) production of isobutyrate, butyrate, and isovalerate + 2 methylbutyrate and reduced acetate to propionate ratio compared to CON and 0.4% aPLA 2 treatments (Table 8) . Feeding MON increases the rumen concentration of propionic acid and decreases concentrations of acetate and butyrate acids (Richardson et al., 1976) ; it also reduces the production of methane, thus enhancing animal performance from the improved retention of carbon and energy in rumen fermentation and increased digestibility of DM, starches, and AA (Bergen and Bates, 1984; Beckett et al., 1998) .
Addition of MON to in vitro incubation of LC substrates increased pH and decreased IVTDMD, H 2 S, and maximal gas production; reduced production of acetate, isobutyrate, butyrate, and isovalerate + 2 methylbutyrate; reduced acetate to propionate ratio; and reduced in vitro production of CH 4 . Addition of MON to in vitro incubation of HC substrates increased pH; decreased in vitro production of CH 4 , isobutyrate, butyrate, and isovalerate + 2 methylbutyrate; and reduced acetate to propionate ratio. However, addition of aPLA 2 to LC and HC substrates had no effect on in vitro fermentation parameters and gas production, suggesting that the effects of aPLA 2 supplementation on animal performance observed on Exp. 1 are independent of rumen fermentation.
